WHO ICTRP trial
Efficacy and Safety of Avatrombopag in Patients with Thrombocytopenia of Ovarian…
ChiCTR2200064890 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2200064890 |
|---|---|
| Public title | Efficacy and Safety of Avatrombopag in Patients with Thrombocytopenia of Ovarian Cancer Treated with Niraparib |
| Scientific title | Efficacy and Safety of Avatrombopag in Patients with Thrombocytopenia of Ovarian Cancer Treated with Niraparib |
| Primary sponsor | Peking Union Medical College Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | Thrombocytopenia in patients with ovarian cancer |
| Interventions | Treatment Group :Avatrombopag |
| Registration date | Oct 20, 2022 |
| Target size | Treatment Group :67 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: